Presentation is loading. Please wait.

Presentation is loading. Please wait.

SIRIUS: A U.S. Multicenter, Randomized, Double-Blind Study of the SIRolImUS-Eluting Stent in De Novo Native Coronary Lesions Presented at TCT 2002.

Published byАндра Ускоковић Modified over 6 years ago

Similar presentations

Presentation on theme: "SIRIUS: A U.S. Multicenter, Randomized, Double-Blind Study of the SIRolImUS-Eluting Stent in De Novo Native Coronary Lesions Presented at TCT 2002."— Presentation transcript:

1 SIRIUS: A U.S. Multicenter, Randomized, Double-Blind Study of the SIRolImUS-Eluting Stent in De Novo Native Coronary Lesions Presented at TCT 2002

2 De Novo Coronary Lesions
SIRIUS: Study Design n = 1,101 patients Control Bx VELOCITYTM n = 545 De Novo Coronary Lesions Diameter: mm Length: mm Sirolimus-eluting Bx VELOCITYTM n = 556 Primary Endpoint: Target vessel failure (TVF) = cardiac death, MI or TVR (FU at 9 months) Angiographic Substudy: First 850 pts (FU at 8 months) IVUS Substudy: 250 pts at selected sites (FU at 8 months) TCT 2002

3 All Randomized Patients n = 1,101
SIRIUS: Study Flow All Randomized Patients n = 1,101 De-registered Sirolimus-eluting Bx VELOCITYTM n = 23 De-registered Control Bx VELOCITYTM n = 20 Sirolimus-eluting Bx VELOCITYTM n = 533 Control Bx VELOCITYTM n = 525 Angio FU at 8 Months = 85.4% Clinical FU at 9 Months = 95.7% Angio FU at 8 Months = 84.7% Clinical FU at 9 Months = 95.8% TCT 2002

4 SIRIUS: 8 Month Angiographic Follow-up Restenosis Rates
In-stent Restenosis In-segment Restenosis 91% reduction p<0.001 75% reduction p<0.001 Sirolimus Stent Bare Stent Sirolimus Stent Bare Stent TCT 2002

5 SIRIUS: 8 Month Angiographic Follow-up Late Lumen Loss
Proximal Margin p<0.001 In-stent p<0.001 Distal Margin p<0.001 Late Lumen Loss (mm) Sirolimus Stent Bare Stent Sirolimus Stent Bare Stent Sirolimus Stent Bare Stent TCT 2002

6 SIRIUS: Restenosis Events Prevented
Number of In-segment Restenosis Events Prevented per 100 Patients All patients Diabetes Small Vessels Long Lesions LAD TCT 2002

7 SIRIUS: Clinical Events Through 9 Months Target Vessel Failure*
MACE Target Vessel Failure* *Primary clinical endpoint; defined as cardiac death, MI, TVR p<0.001 p<0.001 Sirolimus Stent Bare Stent Sirolimus Stent Bare Stent TCT 2002

8 In-segment Restenosis
SIRIUS: Diabetic Patient Restenosis Rates at 8 Month Angiographic Follow-up n = 279 Diabetic Patients In-stent Restenosis In-segment Restenosis 83% reduction p < 0.001 65% reduction p < 0.001 Sirolimus Stent Bare Stent Sirolimus Stent Bare Stent TCT 2002

9 SIRIUS: Patterns of In-stent Restenosis
n = 159 Patients Baseline Lesion Length (mm) Restenosis Lesion Length (mm) p = NS p < 0.001 Sirolimus Stent Bare Stent Sirolimus Stent Bare Stent TCT 2002

10 SIRIUS: LAD Lesion Restenosis Rates at 8 Month Angiographic Follow-up
n = 462 LAD Lesions In-stent Restenosis In-segment Restenosis 95% reduction p < 0.001 76% reduction p < 0.001 Sirolimus Stent Bare Stent Sirolimus Stent Bare Stent TCT 2002

11 SIRIUS: LAD Lesion Clinical Events Through 9 Months Follow-up
n = 462 LAD Lesions MACE Target Lesion Revascularization p < 0.001 p < 0.001 Sirolimus Stent Bare Stent Sirolimus Stent Bare Stent TCT 2002

12 SIRIUS: Overlapping Stent Subgroup 8 Month Angiographic Follow-up
n = 344 Overlapping Stent Subgroup In-stent Restenosis In-segment Restenosis Late Lumen Loss (mm) p < 0.001 p < 0.001 p < 0.001 Sirolimus Stent Bare Stent Sirolimus Stent Bare Stent Sirolimus Stent Bare Stent TCT 2002

Download ppt "SIRIUS: A U.S. Multicenter, Randomized, Double-Blind Study of the SIRolImUS-Eluting Stent in De Novo Native Coronary Lesions Presented at TCT 2002."

Similar presentations

ENDEAVOR IV Acronym: ENDEAVOR IV. Lead investigator: Dr Martin Leon from Columbia University, New York Source: Transcatheter cardiovascular Therapeutics,

ENDEAVOR IV Acronym: ENDEAVOR IV. Lead investigator: Dr Martin Leon from Columbia University, New York Source: Transcatheter cardiovascular Therapeutics,
Www. Clinical trial results.org The C-SIRIUS Study A The Canadian Multi-Center, Randomized, Double-Blind Study of the Sirolimus-Eluting Stent in the Treatment.

Www. Clinical trial results.org The C-SIRIUS Study A The Canadian Multi-Center, Randomized, Double-Blind Study of the Sirolimus-Eluting Stent in the Treatment.
“Real World”: SVG, De Novo or Restenotic Coronary Artery Lesions Chronic Stable Angina, Silent Ischemia, Acute Coronary Syndromes Vessel Diameters:

“Real World”: SVG, De Novo or Restenotic Coronary Artery Lesions Chronic Stable Angina, Silent Ischemia, Acute Coronary Syndromes Vessel Diameters:
Www. Clinical trial results.org The RAVEL Study A RAndomised (double blind) study with the Sirolimus coated BX™ VElocity balloon expandable stent (CYPHER™)

Www. Clinical trial results.org The RAVEL Study A RAndomised (double blind) study with the Sirolimus coated BX™ VElocity balloon expandable stent (CYPHER™)
Four Drug Eluting Stent Trials Keith D Dawkins MD FRCP FACC Southampton University Hospital Keith D Dawkins MD FRCP FACC Southampton University Hospital.

Four Drug Eluting Stent Trials Keith D Dawkins MD FRCP FACC Southampton University Hospital Keith D Dawkins MD FRCP FACC Southampton University Hospital.
Randomized Comparison of FFR-guided and Angiography-guided Provisional Stenting for True Coronary Bifurcation Lesions: The DKCRUSH-VI trial Shao-Liang.

Randomized Comparison of FFR-guided and Angiography-guided Provisional Stenting for True Coronary Bifurcation Lesions: The DKCRUSH-VI trial Shao-Liang.
3rd CEEGI Advisory Board1 Resolute in the DES era: Indications & Limitations Georgios I. Papaioannou, MD, MPH, FACC, FSCAI Athens Medical Center Cardiac.

3rd CEEGI Advisory Board1 Resolute in the DES era: Indications & Limitations Georgios I. Papaioannou, MD, MPH, FACC, FSCAI Athens Medical Center Cardiac.
2 Year Clinical Outcomes from the Pivotal RESOLUTE US Study Laura Mauri MD, MSc on behalf of the RESOLUTE US Investigators Brigham and Women’s Hospital.

2 Year Clinical Outcomes from the Pivotal RESOLUTE US Study Laura Mauri MD, MSc on behalf of the RESOLUTE US Investigators Brigham and Women’s Hospital.
Basel Stent Cost-effectiveness Trial-Late Thrombotic Events (BASKET LATE) Trial Basel Stent Cost-effectiveness Trial-Late Thrombotic Events (BASKET LATE)

Basel Stent Cost-effectiveness Trial-Late Thrombotic Events (BASKET LATE) Trial Basel Stent Cost-effectiveness Trial-Late Thrombotic Events (BASKET LATE)
DIABETES trial P Jiménez-Quevedo, M Sabaté, DJ Angiolillo, JA Gómez-Hospital, R Hernández-Antolín, J Goicolea, F Alfonso, C Bañuelos, J Escaned, R Moreno,

DIABETES trial P Jiménez-Quevedo, M Sabaté, DJ Angiolillo, JA Gómez-Hospital, R Hernández-Antolín, J Goicolea, F Alfonso, C Bañuelos, J Escaned, R Moreno,
Chaim Lotan MD, Yaron Almagor MD, Karel Kuiper MD, M.J. Suttorp MD, William Wijns MD The SICTO Study CYPHER TM Sirolimus-eluting stent in Chronic Total.

Chaim Lotan MD, Yaron Almagor MD, Karel Kuiper MD, M.J. Suttorp MD, William Wijns MD The SICTO Study CYPHER TM Sirolimus-eluting stent in Chronic Total.
Richard Melsheimer Director, Medical Affairs Europe Centocor Eli Lilly and Company Coordinated Use of ReoPro and Drug Eluting Stents: Rationale and Evidence.

Richard Melsheimer Director, Medical Affairs Europe Centocor Eli Lilly and Company Coordinated Use of ReoPro and Drug Eluting Stents: Rationale and Evidence.
The REALITY Study Results. REALITY Study Design The REALITY Study : Prospective randomized clinical trial to evaluate the safety and efficacy of CYPHER®

The REALITY Study Results. REALITY Study Design The REALITY Study : Prospective randomized clinical trial to evaluate the safety and efficacy of CYPHER®
Rapamycin- and Paclitaxel-Eluting Stents With Identical Biodegradable Polymeric Coating and Design Trial Presented at The American College of Cardiology.

Rapamycin- and Paclitaxel-Eluting Stents With Identical Biodegradable Polymeric Coating and Design Trial Presented at The American College of Cardiology.
NOBORI New Generation Drug Eluting Stent Clinical Data Danny Detiege Clinical Manager - Cardiology Terumo Europe N.V. Leuven, Belgium.

NOBORI New Generation Drug Eluting Stent Clinical Data Danny Detiege Clinical Manager - Cardiology Terumo Europe N.V. Leuven, Belgium.
1 of 18 90671521 Presented by Gregg W. Stone, MD, ACC 2011. PROMUS Stent is a private-labeled Xience V Everolimus Eluting Coronary Stent System manufactured.

1 of Presented by Gregg W. Stone, MD, ACC PROMUS Stent is a private-labeled Xience V Everolimus Eluting Coronary Stent System manufactured.
Treatment of In-Stent Restenosis by Paclitaxel Coated PTCA Balloons Presented at The American Heart Association Scientific Session 2006 Presented by Dr.

Treatment of In-Stent Restenosis by Paclitaxel Coated PTCA Balloons Presented at The American Heart Association Scientific Session 2006 Presented by Dr.
SIROLIMUS-ELUTING STENTS EFFECTIVELY INHIBIT NEOINTIMAL PROLIFERATION AS COMPARED TO BARE METAL STENTS IN DISEASED SAPHENOUS VEIN GRAFTS: 6-month IVUS.

SIROLIMUS-ELUTING STENTS EFFECTIVELY INHIBIT NEOINTIMAL PROLIFERATION AS COMPARED TO BARE METAL STENTS IN DISEASED SAPHENOUS VEIN GRAFTS: 6-month IVUS.
TAXUS ATLAS Trial Presented at The EuroPCR meeting Paris, France May 2006 Presented by Dr. Mark Turco TAXUS ATLAS 9-Month Results: Evaluation of TAXUS.

TAXUS ATLAS Trial Presented at The EuroPCR meeting Paris, France May 2006 Presented by Dr. Mark Turco TAXUS ATLAS 9-Month Results: Evaluation of TAXUS.
Basel Stent Cost-Effectiveness (BASKET) Trial BASKET Trial Presented at The European Society of Cardiology Hotline Session 2005 Presented by Dr. Matthias.

Basel Stent Cost-Effectiveness (BASKET) Trial BASKET Trial Presented at The European Society of Cardiology Hotline Session 2005 Presented by Dr. Matthias.

Similar presentations

Ads by Google